International uniform response criteria for multiple myelomaBrian G.M. Durie, Jan Westin, Pieter Sonneveld et al.|Leukemia|2006Cited by 2.6k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, J H Lee, Juan José Lahuerta et al.|Leukemia|2011Cited by 721
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Michel Pavic, Paul G. Richardson et al.|The Lancet|2019Cited by 635
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios Α. Dimopoulos, Evangelos Terpos, Giampaolo Merlini et al.|The Lancet Oncology|2023Cited by 120
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched studyFortunato Morabito, Massimo Offidani, Sara Galimberti et al.|American Journal of Hematology|2013Cited by 26